iBio, Inc. (NASDAQ: IBIO), a leader in AI-driven precision antibody therapies, has announced its participation in the Guggenheim 2nd Annual Healthcare Innovation Conference. This significant event is scheduled for November 10-12, 2025, in Boston.
During the conference, Martin Brenner, DVM, Ph.D., who serves as both the Chief Executive Officer and Chief Scientific Officer of iBio, will engage in a fireside chat on Monday, November 10, 2025, at 8:30 a.m. ET. He will discuss the company”s ongoing journey towards becoming a clinical-stage biotechnology firm and share insights into the advancements in iBio”s innovative obesity pipeline.
Dr. Brenner will also elaborate on how iBio”s unique antibody programs are designed to complement existing obesity treatments, aiming to generate long-term value through innovation and scientific leadership. Additionally, Felipe Duran, iBio”s Chief Financial Officer, will join Dr. Brenner for individual meetings throughout the conference.
For those unable to attend in person, a livestream of the event will be available, with a replay link provided on the investor section of the iBio website.
About iBio, Inc.: iBio is a pioneering biotechnology company that utilizes artificial intelligence and advanced computational biology to create next-generation biopharmaceuticals targeting cardiometabolic diseases, obesity, cancer, and other challenging medical conditions. By integrating proprietary 3D modeling with cutting-edge drug discovery platforms, iBio is developing a pipeline of breakthrough antibody therapies to address significant unmet medical needs. The company”s mission focuses on transforming drug discovery processes, shortening development timelines, and enhancing the potential of precision medicine.
For additional details, visit www.ibioinc.com or connect with us on LinkedIn.
Forward-Looking Statements: This press release contains forward-looking statements as defined by federal securities laws. Terms such as “may,” “will,” “should,” “expect,” “anticipate,” and similar expressions indicate forward-looking statements. These statements reflect current estimates and assumptions and include projections about the company”s ongoing development as a clinical-stage biotechnology entity, advancements in its obesity pipeline, and the efficacy of its antibody programs. While iBio believes these projections are realistic, actual results could differ due to various risks and uncertainties.
Key factors influencing actual outcomes include the company”s ability to initiate clinical trials, secure regulatory approvals, and the market acceptance of its product candidates. Additional risks are detailed in iBio”s filings with the SEC, including the Annual Report on Form 10-K for the year ending June 30, 2025, and subsequent filings on Forms 10-Q and 8-K. iBio is not obligated to update any forward-looking statements unless legally required.
Corporate Contact: iBio, Inc. Investor Relations: [email protected]
Media Contacts: Ignacio Guerrero-Ros, Ph.D., or David Schull, Russo Partners, LLC. Contact via email at [email protected] or [email protected]. Phone: (858) 717-2310 or (646) 942-5604.
